Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Rises By 13.2%

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 1,720,000 shares, a growth of 13.2% from the December 31st total of 1,520,000 shares. Approximately 5.2% of the shares of the company are sold short. Based on an average daily volume of 773,000 shares, the short-interest ratio is currently 2.2 days.

Hedge Funds Weigh In On Werewolf Therapeutics

Several hedge funds have recently modified their holdings of HOWL. American Century Companies Inc. grew its stake in Werewolf Therapeutics by 50.7% during the second quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock valued at $92,000 after acquiring an additional 12,656 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Werewolf Therapeutics by 43.9% during the second quarter. Dimensional Fund Advisors LP now owns 160,577 shares of the company’s stock valued at $392,000 after purchasing an additional 48,952 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Werewolf Therapeutics by 103.1% in the second quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock worth $417,000 after purchasing an additional 86,800 shares during the last quarter. Marshall Wace LLP lifted its position in shares of Werewolf Therapeutics by 410.5% in the second quarter. Marshall Wace LLP now owns 134,184 shares of the company’s stock worth $327,000 after buying an additional 107,900 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in Werewolf Therapeutics by 96.4% during the second quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock valued at $2,709,000 after buying an additional 544,881 shares during the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Price Performance

HOWL stock traded up $0.02 during midday trading on Monday, hitting $1.36. The company’s stock had a trading volume of 49,119 shares, compared to its average volume of 265,827. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29. Werewolf Therapeutics has a 12 month low of $1.26 and a 12 month high of $8.19. The company has a 50 day moving average of $1.58 and a two-hundred day moving average of $2.01. The firm has a market capitalization of $60.38 million, a price-to-earnings ratio of -0.87 and a beta of 0.36.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on HOWL shares. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Werewolf Therapeutics in a research note on Tuesday, November 19th. JMP Securities decreased their price objective on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research report on Tuesday, January 14th.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.